Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma.

Tetsushi MurakamiTakeo KosakaHiroki IdeYuta UmezawaTakayuki TakahashiMizuki IzawaKyohei HakozakiKeisuke ShigetaKoichiro OgiharaHiroaki KobayashiKunimitsu KanaiTakahiro MaedaShunsuke YoshimineRyuichi MizunoKoshiro NishimotoMototsugu Oya

Published in: BJUI compass (2021)

Dose reductions in cisplatin due to renal dysfunction did not worsen clinical outcomes for metastatic UC.

Keyphrases

oxidative stress
squamous cell carcinoma
small cell lung cancer
type diabetes
robot assisted
glycemic control